At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 744 enrolled
Drug / intervention
Standard of Care (SOC) Migraine Preventive Medication +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine
In Brief
A Phase 3 clinical trial evaluating Standard of Care (SOC) Migraine Preventive Medication and Atogepant for Episodic Migraine. Completed, enrolled 744 participants across 112 sites.
Detailed Summary
This study will evaluate safety and tolerability of treatment with atogepant for the prevention of episodic migraine over the course of one year.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpisodic Migraine
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
Enrollment StartOct 2018
First PostedOct 2018
Primary CompletionMay 2020
TodayJul 2026
First PostedOct 9, 2018
Enrollment StartOct 8, 2018
Primary CompletionMay 21, 2020
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 7.7 years ago
Interventions
Standard of Care (SOC) Migraine Preventive Medicationdrug
Standard of care medication selected based on investigator's judgement, recognized as safe and effective for the prevention of migraine.
Atogepantdrug
Atogepant tablets taken orally, once daily for 52 weeks.